Discontinuation of thioridazine

BMJ

Volumn 325, Issue 7370, 2002, Pages 967-

  Bisset, Ann F ^a   Arshad, Pernia ^a   Morcos, Mary ^a   Sridharan, Baskaran ^a  

^a Information and Statistics Division   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NEUROLEPTIC AGENT; RISPERIDONE; THIORIDAZINE; TRANQUILIZER;

AGITATION; ANXIETY; DRUG COST; DRUG WITHDRAWAL; HUMAN; HYPOMANIA; LETTER; MANIA; PRIORITY JOURNAL; SIDE EFFECT; DRUG LEGISLATION; NOTE; PSYCHOSIS; SAFETY;

ANTIPSYCHOTIC AGENTS; HUMANS; LEGISLATION, DRUG; PSYCHOTIC DISORDERS; SAFETY; THIORIDAZINE;

EID: 0037180226     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.325.7370.967/a     Document Type: Letter

References (5)

1. Davies SJC, Cooke LB, Moore AG, Potokar J. Discontinuation of thioridazine in patients with learning disabilities: balancing cardiovascular toxicity with adverse consequences of changing drugs. BMJ 2002; 324: 1519–1521. (22 June.)
2. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287: 2215–2220.
3. Davies SJC, Cooke LB, Moore AG, Potokar J. Discontinuation of thioridazine in patients with learning disabilities: balancing cardiovascular toxicity with adverse consequences of changing drugs. BMJ 2002; 324: 1519–1521. (22 June.)
4. Vander Ben Borre R. Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double blind placebo-controlled cross-over study. Acta Psychiatrica Scandinavica 1993; 87: 167–171.
5. Mos J, Van Aken HH, Van Oorschot R, Olivier B. Chronic treatment with eltoprazine does not lead to tolerance in its anti-aggressive actions, in contrast to haloperidol. Eur Neuropsychopharmacol 1996; 6: 1–7.